Abstract
By the end of 2000, 11 monoclonal antibody-based therapeutic agents had gained regulatory approval within the European Union. Approximately 59 such products are currently undergoing evaluation, ensuring that the number of approved products will increase substantially during the next few years.
| Original language | English |
|---|---|
| Pages (from-to) | 70+72+74+76 |
| Journal | Pharmaceutical Technology Europe |
| Volume | 13 |
| Issue number | 3 |
| Publication status | Published - 2001 |
